Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Fullerton, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Riverside, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Roseville, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
San Diego, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Brandon, FL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Brandon, FL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Panama City, FL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
South Miami, FL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
South Miami, FL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Madisonville, KY
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Madisonville, KY
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Lafayette, LA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Lafayette, LA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Sunset, LA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Sunset, LA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Charlotte, NC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Charleston, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Union, SC
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Houston, TX
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Abingdon, VA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Abingdon, VA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Richmond, VA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
La Plata,
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
La Plata,
Click here to add this to my saved trials
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Status: Enrolling
Updated:  9/11/2017
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Status: Enrolling
Updated: 9/11/2017
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Status: Enrolling
Updated:  9/11/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Status: Enrolling
Updated: 9/11/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Status: Enrolling
Updated:  9/11/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications
Status: Enrolling
Updated: 9/11/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults
Status: Enrolling
Updated:  9/14/2017
Johnson County Clin-Trials
mi
from
Lenexa, KA
Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults
Status: Enrolling
Updated: 9/14/2017
Johnson County Clin-Trials
mi
from
Lenexa, KA
Click here to add this to my saved trials
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Status: Enrolling
Updated:  9/14/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Status: Enrolling
Updated: 9/14/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Birmingham, AL
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Wilmington, DE
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Wilmington, DE
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Chicago, IL
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Iowa City, IA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Boston, MA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Minneapolis, MN
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Kansas City, MO
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Omaha, NE
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Cleveland, OH
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Dayton, OH
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Charleston, SC
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Charlottesville, VA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Norfolk, VA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Richmond, VA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Madison, WI
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials